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Abstract 
OBJECTIVES: Advanced chronic heart failure (ACHF) is progressive with poor prognosis and quality of life (QoL). Heart 
transplantation (HTx) is an effective treatment for ACHF, but is limited by scarcity of donor hearts. Left ventricular assist device (LVAD) 
support is a useful bridging therapy, and short- and medium-term outcomes have improved. We investigated QoL in patients assessed 
for HTx, awaiting HTx and after HTx. 
METHODS: We carried out a cross-sectional survey across four groups: Group 1—patients assessed for HTx, Group 2—patients listed 
for HTx on medical therapy, Group 3—patients supported with LVAD and Group 4—patients after HTx. Two questionnaires, the 
Kansas City Cardiomyopathy Questionnaire (KCCQ) and the EuroQol dimensions (EQ-5D), were administered in all adult HTx centres in 
the UK. Scores calculated for the KCCQ and EQ-5D were compared. 
RESULTS: Three hundred and eighty-six patients completed questionnaires: 194 in Group 1, 28 in Group 2, 82 in Group 3 and 82 in 
Group 
4. Patients after HTx reported the best QoL [KCCQ overall summary score: mean 73.0 (SD 27.2)]; patients with LVAD reported better 
QoL than those being assessed for HTx and those listed for HTx on medical therapy [overall summary score; LVAD: 52.6 (22.0), 
Listed on medical therapy: 33.3 (21.1), Assessment: 35.5 (21.5)]. Similarly, EQ-5D scores were highest in patients after HTx [HTx: mean 
0.74 (0.27); LVAD: 0.58 (0.26), Listed on medical therapy: 0.44 (0.27), Assessment: 0.50 (SD 0.30)]. 
CONCLUSIONS: Patients supported with LVAD had a signiﬁcantly better QoL than those awaiting HTx without LVAD support, 
although HTx patients reported the best QoL. 
 
INTRODUCTION 
 
Heart failure (HF) is a progressive condition and advanced chronic HF (ACHF) is associated with a poor prognosis and poor quality of life 
(QoL) [1, 2]. Heart transplantation (HTx) is an effective treat- ment for selected patients, but it is limited by the scarcity of suit- able 
donor hearts, resulting in increasing waiting times before transplantation [3]. 
Left ventricular assist devices (LVADs) have been used as an adjunct to HTx, bridging patients to transplant when organs have not 
been available and this has become more frequent due to the scarcity of donor hearts [4]. Currently, in the UK, LVAD support is 
restricted to bridging patients to transplantation because of concern regarding the cost and cost-effectiveness of such therapies 
[5].QoL has been shown to improve after LVAD implantation and after HTx [6–11]. However, a direct comparison of transplant can- 
didates receiving medical therapy, LVAD support  and  after  HTx has not been undertaken. Here, we report the results of a multicentre 
cohort study of QoL in ACHF patients. 
 
 
METHODS 
 
The UK Cardiothoracic Transplant Audit (UKCTA) is an ongoing pro- spective cohort study involving all UK HTx centres, which has col- 
lected data on all patients listed for HTx and patients who received allografts since April 1995. Data on LVAD activity and outcome 
(demographic  data  and  follow-up  data  for  survival,  explant  andtransplant) have been collected since 2002. In 2006, a more com- 
prehensive database of VAD activity and outcome was established for the purposes of audit and research. This study was conducted by the 
UKCTA with participation of all UK HTx centres as an extension of the national audit agreed between commissioners and centres. 
Additional QoL data were collected over an 18-month period. 
 
Participants and recruitment 
 
Questionnaires were distributed to patients within four deﬁned populations when they attended hospital over an 18-month period 
between January 2011 and August 2012. 
We included all adult patients assessed for HTx (Group 1: Assessment); all patients listed for HTx without an LVAD in situ (Group 2: 
Listed for HTx on medical therapy); all patients with an LVAD in situ (Group 3: LVAD) and all adult patients (aged 16 years or more) who 
underwent HTx between January 2009 and December 2010 (Group 4: post-HTx). 
All NHS adult HTx centres participated in the study. These are the Royal Brompton and Hareﬁeld Trust, Hareﬁeld Hospital (London), Queen 
Elizabeth Hospital (Birmingham), Papworth Hospital (Cambridge), Freeman Hospital (Newcastle), Wythenshawe Hospital (Manchester) and 
Golden Jubilee Hospital (Glasgow). 
Completed questionnaires were returned to the Royal College of Surgeons of England (RCS) where they were entered into a purpose- 
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designed database. The questionnaires included a minimal set of identiﬁers that allowed the data to be linked to the UKCTA transplant 
and VAD databases to  determine the patient group. The UKCTA transplant database includes all patients listed for HTx and all patients 
who have received HTx, whereas the VAD database includes all NHS patients who have had LVAD support. Questionnaires which could not 
be successfully linked to either database were checked with the centre to conﬁrm they were returned by a patient being assessed for 
HTx. The audit does not routinely collect data on patients being assessed for HTx. 
 
Quality-of-life instruments 
 
The validated QoL instruments used included one disease-speciﬁc measure: the Kansas City Cardiomyopathy Questionnaire (KCCQ) 
and one generic measure: the EuroQol 5 dimensions (EQ-5D) [12]. The  KCCQ  is  a  23-item  questionnaire  developed  to  describe QoL 
in patients with HF. It quantiﬁes physical limitation; symptom stability, frequency and burden; QoL; social interference and self- efﬁcacy. 
These scores are then used to derive a total symptom score, overall summary score and clinical summary score [12]. The KCCQ was 
chosen in preference to other disease-speciﬁc measures due to its excellent sensitivity to clinical change in patients with HF [12, 13]. A 
5-point change in the overall summary score longitu- dinally is considered to reﬂect a clinically signiﬁcant change in HF 
status [12]. For all scores, higher values indicate a better QoL. 
The EQ-5D deﬁnes health in ﬁve dimensions: morbidity, self- care, usual activities, pain or discomfort, anxiety or depression, 
which are combined to give a state score [14]. The EQ-5D has a broader user base than the KCCQ and is well recognized as a generic 
measure which is short and easy to use for both the ad- ministrator and the patient. Again, higher state scores represent a better 
QoL. A value of 1 indicates full health and a value of less than zero indicates a QoL worse than death. The EQ-5D also returns scores 
from a visual analogue scale, a self-reported per- centage where 100% represents full health. 
 
Statistical methods 
 
Continuous variables are summarized using a mean and standard deviation or median and interquartile range if the distribution is skewed, 
and categorical variables are reported as a number and per- centage. Patient characteristics are compared using the Kruskal– Wallis test 
(continuous variables with a skewed distribution) and χ2 test (category variables with expected frequencies greater than 5). Questionnaire 
scores are compared using analysis of variance (con- tinuous variables with an approximate normal distribution). Statistical analyses were 
carried out using Stata version 11.2. 
 
Ethics 
 
Ethical approval was not required for this study as conﬁrmed by the UK National Ethics Service. 
 
RESULTS 
Questionnaires completed 
 
Questionnaires were received from the six HTx centres during the study period. In total, 389 patients returned a questionnaire; 3 
were excluded from the analysis due to the lack of sufﬁcient iden- tiﬁers to facilitate data linkage, leaving 386 questionnaires. Case 
ascertainment was not complete; centre coordinators adminis- tered questionnaires when the patient attended hospital and patient 
participation was voluntary. In total, 286 patients  were listed for HTx within the study period; questionnaires were returned from 
194 patients assessed for HTx (not all of whom will have subsequently been listed for HTx) and 110 patients on the national waiting 
list (28 on medical therapy and 82 with an LVAD in situ). Overall, 180 HTx were carried out between January 2009 and December 
2010 and questionnaires were returned by 82 patients post-HTx. The median time from HTx to questionnaire completion was 332 
days [interquartile range (IQR) 168–623 days]. 
 
Patient demographics 
 
Patient demographics of the four patient groups are summarized in Table 1. The median age was 50.1 years (IQR 41.1–57.8, n = 385). 
Hypertension was more prevalent among post-HTx recipients and previous stroke occurred more frequently in patients with an LVAD. 
Employment status differed signiﬁcantly across the groups (P = 0.005). Proportionally more patients were in paid employed at 
assessment (34.8%) and after HTx (34.7%) than at other times (16% if listed on medical therapy and 20% with LVAD support). 
 
Kansas City Cardiomyopathy Questionnaire scores 
 
The 10 KCCQ summary scores are given in Table 2 and Fig. 1. Both patients being assessed for HTx and those listed on medical therapy 
consistently reported worse mean scores than those with LVAD support. The post-HTx group reported the best mean QoL scores in 
most modalities (exceptions being symptom stability and self-efﬁcacy scores). The symptom stability scores were best in the LVAD group; 
mean 60.9 in the patients with LVAD compared with 
54.7 in the post-HTx group. Patients with LVAD reported similar self-efﬁcacy mean scores to the post-HTx group. 
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LVAD: left ventricular assist device; HTx: heart transplantation; IQR: interquartile range. 
*Kruskal–Wallis test. 
**Chi-squared test. 
Total symptom score and clinical summary score have been grouped together with domains that contribute to the summary score. 
KCCQ: Kansas City Cardiomyopathy Questionnaire; EQ-5D: EuroQol dimensions; QoL: quality of life; LVAD: left ventricular assist device; HTx: heart 
transplantation; IQR: interquartile range. 
*Analysis of variance. 
 
 
Table 1:  Self-reported patient demography 
and comorbidity 
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Table 2:   KCCQ and EQ-5D scores: higher scores imply better performance within domains 
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EuroQol 5 dimension scores 
 
EQ-5D index scores are given in Table 2 and Fig. 1. Patients in the LVAD group reported better EQ-5D index scores than medically 
treated ACHF patients and assessed patients. QoL scores reported by post-HTx patients were better than in all other groups. 
 
DISCUSSION 
 
There are three main ﬁndings of our study. First, patients with ACHF receiving medical therapy, those being assessed for HTx and 
those awaiting HTx without LVAD had very poor QoL. Second, HTx was the most effective surgical treatment in terms of QoL 
achieved. Third, patients receiving LVAD support for ACHF had a better QoL than those receiving medical treatment despite LVAD 
patients having been selected, because they were refractory to medical treatment. 
 
Many studies have documented a poor QoL in ACHF, and the impact appears to be related to the stage of the disease [7, 8, 10, 15]. 
Our study conﬁrmed this ﬁnding with similar KCCQ and EQ5D results to those reported by others. Previous studies have demon- strated 
that both HTx and LVAD support can improve QoL in ACHF [6–8, 10]. A recent study showed improved QoL at 3 months fol- lowing HTx 
and LVAD implantation, with an associated increase in levels of habitual physical activity. This was compared with a poorer QoL and 
lower physical activity in ACHF patients not undergoing HTx or LVAD [16]. Our study is the ﬁrst to directly compare QoL in ACHF 
patients receiving medical therapy while awaiting HTx, LVAD support as a bridge to HTx and after HTx. 
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Figure 1: Median scores and interquartile ranges by the study group [assessment group in red (n = 194), medical therapy in 
blue (n = 28), LVAD in green (n = 82) and post-HTx in yellow (n = 82)]. LVAD: left ventricular assist device; HTx: heart 
transplantation; EQ-5D: EuroQol dimensions. 
 
Our study population consisted of ACHF patients within the UK pathway leading to HTx. This pathway involved several stages: refer- ral 
for HTx assessment and selective listing for HTx, HTx when organs are available or LVAD implantation in the absence of HTx when 
patients deteriorate. Questionnaire administration time points were chosen to reﬂect these key stages within the HTx pathway. 
Due to advances in LVAD technology, patients with ACHF refrac- tory to medical therapy now have two options. HTx provides best 
long-term outcome in selected patients, but scarcity of organs means this treatment has a limited availability and the waiting period is 
long. HTx activity in the UK has decreased in recent years [3], leading to an increasing need for LVAD support [4]. 
Patients receiving medical treatment for ACHF and being listed for HTx reported the worst QoL in all domains. QoL was best after 
HTx. Almost all QoL summary scores in patients with HTx were signiﬁcantly better than all other treatment groups. This may be 
related to the lower  functional capacity of LVAD  patients com- pared with HTx recipients [2–4]. 
The most important ﬁnding in our study was that patients receiv- ing LVAD support report QoL scores that are better than medically 
treated patients despite the fact that patients who were being treated medically were deemed to be ‘too well’ to currently require an 
LVAD. Patients selected for LVAD were refractory to medical therapy, more unwell and less stable than those on medical therapy. Despite 
this, LVAD patients reported a signiﬁcantly better QoL in all domains [10]. 
Patients with LVAD support report worse scores for speciﬁc elements of physical limitation such as showering. This is expected due to 
driveline protrusion from the skin, which makes showering and washing more difﬁcult for LVAD patients, necessitating special 
precautions. 
 
 
Strengths and limitations 
 
This is the ﬁrst comprehensive national cohort study to compare QoL in ACHF patients who are potentially eligible for HTx. As is 
common with patient-completed questionnaires, the response rate was incomplete. No data were collected on those who declined 
to participate, so we are unable to assess whether those who participated are representative of the cohort as a whole. The limited 
duration of this study mandated a cross-sectional study design. In future, longitudinal studies may be able to directly observe the 
effect on QoL of patients moving from medical therapy to LVAD support and ultimately HTx. 
We used two of the best known questionnaires to detect clinical changes in HF. Patients who have undergone HTx have 
technically been ‘cured’ of ACHF and this caused some confusion for certain patients when answering questions regarding 
‘their’ ACHF. The questionnaires were used to capture snapshots of QoL within patient episodes and were therefore not 
able to completely reﬂect the potential instability of QoL in ACHF patients with chan- ging disease states. There are no 
speciﬁc questionnaires devel- oped with good validation for support with a continuous-ﬂow LVAD; any such QoL 
instrument would collect data related to spe- ciﬁc issues such as restricted activities and showering and problems 
related to driveline and system care. 
Data characterizing the study cohort was limited, particularly for the Group 1 patients referred to HTx assessment; 
these patients are a heterogeneous group; some will go on to be listed for HTx, some will be considered unsuitable for 
HTx and others may not be ready for listing but will continue to be monitored. This patient group is not included in 
the national audit currently and the outcome of the assessment process is unknown. Similarly, Group 2 patients who were 
listed for HTx under optimal medical treatment include patients in a stable condition and patients with a progressive 
deterioration that may lead them to require an LVAD and/or an urgent HTx. 
 
 
CONCLUSION 
 
This study has found that LVAD support provided a signiﬁcantly better QoL for ACHF patients awaiting HTx than 
continued medical therapy. However, HTx recipients had an even better QoL and HTx remains the gold standard 
treatment for such patients when suitable donor hearts are available. 
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